These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 17485191)

  • 1. Validation and implementation of drug-dependent antibody assays in clinical trials for safety monitoring of patients dosed with roxifiban, an orally bioavailable glycoprotein IIb/IIIa antagonist.
    Barrett YC; Ebling W; Pieniaszek H; Billheimer J; Seiffert D
    J Pharm Biomed Anal; 2007 Aug; 44(4):938-46. PubMed ID: 17485191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence that thrombocytopenia observed in humans treated with orally bioavailable glycoprotein IIb/IIIa antagonists is immune mediated.
    Billheimer JT; Dicker IB; Wynn R; Bradley JD; Cromley DA; Godonis HE; Grimminger LC; He B; Kieras CJ; Pedicord DL; Spitz SM; Thomas BE; Zolotarjova NI; Gorko MA; Hollis GF; Daly RN; Stern AM; Seiffert D
    Blood; 2002 May; 99(10):3540-6. PubMed ID: 11986205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective testing for drug-dependent antibodies reduces the incidence of thrombocytopenia observed with the small molecule glycoprotein IIb/IIIa antagonist roxifiban: implications for the etiology of thrombocytopenia.
    Seiffert D; Stern AM; Ebling W; Rossi RJ; Barrett YC; Wynn R; Hollis GF; He B; Kieras CJ; Pedicord DL; Cromley DA; Hua TA; Stein RB; Daly RN; Sferruzza A; Pieniaszek HJ; Billheimer JT
    Blood; 2003 Jan; 101(1):58-63. PubMed ID: 12393571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of roxifiban (DMP754), a novel oral platelet glycoprotein IIb/IIIa receptor inhibitor, in patients with stable coronary artery disease.
    Murphy J; Wright RS; Gussak I; Williams B; Daly RN; Cain VA; Pieniaszek HJ; Sy SK; Ebling W; Simonson K; Wilcox RA; Kopecky SL
    Am J Cardiovasc Drugs; 2003; 3(2):101-12. PubMed ID: 14727937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, tolerability, pharmacokinetics, and time course of pharmacologic response of the active metabolite of roxifiban, XV459, a glycoprotein IIb/IIIa antagonist, following oral administration in healthy volunteers.
    Pieniaszek HJ; Sy SK; Ebling W; Fossler MJ; Cain VA; Mondick JT; Ma S; Kornhauser DM
    J Clin Pharmacol; 2002 Jul; 42(7):738-53. PubMed ID: 12092741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of the glycoprotein IIb/IIIa antagonist Roxifiban on P-selectin expression, fibrinogen binding, and microaggregate formation in a phase I dose-finding study: no evidence for platelet activation during treatment with a glycoprotein IIb/IIIa antagonist.
    Seiffert D; Thomas BE; Bradley JD; Munzer DA; Tchinnes MA; Kornhauser DM; Cain VA; Hua TA; Feuerstein GZ; Martin DE; Stern AM
    Platelets; 2003 May; 14(3):179-87. PubMed ID: 12850842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimization and validation of chiral high-performance liquid chromatographic method for analysis of a fibrinogen (gpIIb/IIIa) receptor antagonist.
    Williams RC; Miyawa JH; Boucher RJ; Brockson RW
    J Chromatogr A; 1999 Jun; 844(1-2):171-9. PubMed ID: 10399330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification and characterization of antibodies that bind GPIIb/IIIa: antagonist complexes.
    Breth L; Kochie J; Combs A; Wang S; Smallheer J; Billheimer J; Seiffert D; Hollis G; O'Neil K
    J Immunol Methods; 2005 Jun; 301(1-2):11-20. PubMed ID: 15992818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ceftriaxone causes drug-induced immune thrombocytopenia and hemolytic anemia: characterization of targets on platelets and red blood cells.
    Grossjohann B; Eichler P; Greinacher A; Santoso S; Kroll H
    Transfusion; 2004 Jul; 44(7):1033-40. PubMed ID: 15225244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Solid-state carbon NMR characterization of the polymorphs of roxifiban.
    Vickery RD; Nemeth GA; Maurin MB
    J Pharm Biomed Anal; 2002 Aug; 30(1):125-9. PubMed ID: 12151072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simultaneous quantification of seven active metabolites of roxifiban in human plasma by LC/MS/MS in the presence of an interfering displacer at millimolar concentrations.
    Shi G; Lloyd TL; Sy SK; Jiao Q; Wernicki A; Mutlib A; Emm TA; Unger SE; Pieniaszek HJ
    J Pharm Biomed Anal; 2003 Apr; 31(5):937-51. PubMed ID: 12684106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using thrombelastography to determine the efficacy of the platelet glycoprotein IIb/IIIa antagonist, roxifiban, on platelet/fibrin-mediated clot dynamics in humans.
    Mousa SA; Bozarth JM; Seiffert D; Feuerstein GZ
    Blood Coagul Fibrinolysis; 2005 Apr; 16(3):165-71. PubMed ID: 15795533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The emerging role of platelet glycoprotein IIb/IIIa inhibitors in managing high-risk patients with non-ST segment elevation acute coronary syndromes.
    Bolognese L
    Curr Med Res Opin; 2007 Jun; 23(6):1217-26. PubMed ID: 17559721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis.
    O'Donoghue M; Antman EM; Braunwald E; Murphy SA; Steg PG; Finkelstein A; Penny WF; Fridrich V; McCabe CH; Sabatine MS; Wiviott SD
    J Am Coll Cardiol; 2009 Aug; 54(8):678-85. PubMed ID: 19679245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interactions between heparins, glycoprotein IIb/IIIa antagonists, and coronary intervention. The Global Registry of Acute Coronary Events (GRACE).
    Brieger D; Van de Werf F; Avezum A; Montalescot G; Kennelly BM; Granger CB; Goodman SG; Dabbous OH; Agnelli G;
    Am Heart J; 2007 Jun; 153(6):960-9. PubMed ID: 17540196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of platelet glycoprotein IIb-IIIa number and glycoprotein IIIa Leu33Pro polymorphism on platelet aggregation and sensitivity to glycoprotein IIb-IIIa antagonists.
    Sirotkina OV; Khaspekova SG; Zabotina AM; Shimanova YV; Mazurov AV
    Platelets; 2007 Nov; 18(7):506-14. PubMed ID: 17957566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mass spectrometric and NMR characterization of metabolites of roxifiban, a potent and selective antagonist of the platelet glycoprotein IIb/IIIa receptor.
    Mutlib AE; Diamond S; Shockcor J; Way R; Nemeth G; Gan L; Christ DD
    Xenobiotica; 2000 Nov; 30(11):1091-110. PubMed ID: 11197070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measuring soluble platelet glycoprotein VI in human plasma by ELISA.
    Al-Tamimi M; Mu FT; Moroi M; Gardiner EE; Berndt MC; Andrews RK
    Platelets; 2009 May; 20(3):143-9. PubMed ID: 19437330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of immunoassays for the measurement of erythropoietin (EPO) as an indirect biomarker of recombinant human EPO misuse in sport.
    Abellan R; Ventura R; Pichini S; Remacha AF; Pascual JA; Pacifici R; Di Giovannandrea R; Zuccaro P; Segura J
    J Pharm Biomed Anal; 2004 Sep; 35(5):1169-77. PubMed ID: 15336362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes with the use of glycoprotein IIb/IIIa inhibitors in non-ST-segment elevation acute coronary syndromes.
    Dabbous OH; Anderson FA; Gore JM; Eagle KA; Fox KA; Mehta RH; Goldberg RJ; Agnelli G; Steg PG;
    Heart; 2008 Feb; 94(2):159-65. PubMed ID: 17575335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.